Search

Your search keyword '"Usala, E."' showing total 97 results
Start Over Author "Usala, E."
97 results on '"Usala, E."'

1. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

2. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, MT., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, SF., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, AM., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, EM., Luppi, M., Marasca, R., Pogliani, EM., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, MC., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, AM., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., and DʼEmilio, A.

Published
2015
Full Text
View/download PDF

3. Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia

Author

Fontana, D, Ramazzotti, D, Aroldi, A, Redaelli, S, Magistroni, V, Pirola, A, Niro, A, Massimino, L, Mastini, C, Brambilla, V, Bombelli, S, Bungaro, S, Morotti, A, Rea, D, Stagno, F, Martino, B, Campiotti, L, Caocci, G, Usala, E, Merli, M, Onida, F, Bregni, M, Elli, E, Fumagalli, M, Ciceri, F, Perego, R, Pagni, F, Mologni, L, Piazza, R, Gambacorti-Passerini, C, Fontana, Diletta, Ramazzotti, Daniele, Aroldi, Andrea, Redaelli, Sara, Magistroni, Vera, Pirola, Alessandra, Niro, Antonio, Massimino, Luca, Mastini, Cristina, Brambilla, Virginia, Bombelli, Silvia, Bungaro, Silvia, Morotti, Alessandro, Rea, Delphine, Stagno, Fabio, Martino, Bruno, Campiotti, Leonardo, Caocci, Giovanni, Usala, Emilio, Merli, Michele, Onida, Francesco, Bregni, Marco, Elli, Elena Maria, Fumagalli, Monica, Ciceri, Fabio, Perego, Roberto A, Pagni, Fabio, Mologni, Luca, Piazza, Rocco, Gambacorti-Passerini, Carlo, Fontana, D, Ramazzotti, D, Aroldi, A, Redaelli, S, Magistroni, V, Pirola, A, Niro, A, Massimino, L, Mastini, C, Brambilla, V, Bombelli, S, Bungaro, S, Morotti, A, Rea, D, Stagno, F, Martino, B, Campiotti, L, Caocci, G, Usala, E, Merli, M, Onida, F, Bregni, M, Elli, E, Fumagalli, M, Ciceri, F, Perego, R, Pagni, F, Mologni, L, Piazza, R, Gambacorti-Passerini, C, Fontana, Diletta, Ramazzotti, Daniele, Aroldi, Andrea, Redaelli, Sara, Magistroni, Vera, Pirola, Alessandra, Niro, Antonio, Massimino, Luca, Mastini, Cristina, Brambilla, Virginia, Bombelli, Silvia, Bungaro, Silvia, Morotti, Alessandro, Rea, Delphine, Stagno, Fabio, Martino, Bruno, Campiotti, Leonardo, Caocci, Giovanni, Usala, Emilio, Merli, Michele, Onida, Francesco, Bregni, Marco, Elli, Elena Maria, Fumagalli, Monica, Ciceri, Fabio, Perego, Roberto A, Pagni, Fabio, Mologni, Luca, Piazza, Rocco, and Gambacorti-Passerini, Carlo

Abstract

Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1-negative clonal disorder, which belongs to the myelodysplastic/myeloproliferative group. This disease is characterized by recurrent somatic mutations in SETBP1, ASXL1 and ETNK1 genes, as well as high genetic heterogeneity, thus posing a great therapeutic challenge. To provide a comprehensive genomic characterization of aCML we applied a high-throughput sequencing strategy to 43 aCML samples, including both whole-exome and RNA-sequencing data. Our dataset identifies ASXL1, SETBP1, and ETNK1 as the most frequently mutated genes with a total of 43.2%, 29.7 and 16.2%, respectively. We characterized the clonal architecture of 7 aCML patients by means of colony assays and targeted resequencing. The results indicate that ETNK1 variants occur early in the clonal evolution history of aCML, while SETBP1 mutations often represent a late event. The presence of actionable mutations conferred both ex vivo and in vivo sensitivity to specific inhibitors with evidence of strong in vitro synergism in case of multiple targeting. In one patient, a clinical response was obtained. Stratification based on RNA-sequencing identified two different populations in terms of overall survival, and differential gene expression analysis identified 38 significantly overexpressed genes in the worse outcome group. Three genes correctly classified patients for overall survival.

Published
2020

5. S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Author

Malagola, M., primary, Efficace, F., additional, Polverelli, N., additional, Cottone, F., additional, Abruzzese, E., additional, Iurlo, A., additional, Bucelli, C., additional, Stagno, F., additional, Bonifacio, M., additional, D’Adda, M., additional, Lunghi, M., additional, Crugnola, M., additional, Lunghi, F., additional, Castagnetti, F., additional, Rosti, G., additional, Ferrari, M.L., additional, Bergamaschi, M., additional, Binotto, G., additional, Sancetta, R., additional, Coppi, M.R., additional, Giai, V., additional, Rege Cambrin, G., additional, Romano, A., additional, Tiribelli, M., additional, Russo, S., additional, Aprile, L., additional, Falcone, A.P., additional, Rupoli, S., additional, Russo Rossi, A., additional, Usala, E., additional, Martino, B., additional, Gandolfi, L., additional, Bernardi, S., additional, Zanaglio, C., additional, Farina, M., additional, Baccarani, M., additional, and Russo, D., additional

Published
2019
Full Text
View/download PDF

6. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

Author

Piazza, R, Magistroni, V, Redaelli, S, Mauri, M, Massimino, L, Sessa, A, Peronaci, M, Lalowski, M, Soliymani, R, Mezzatesta, C, Pirola, A, Banfi, F, Rubio, A, Rea, D, Stagno, F, Usala, E, Martino, B, Campiotti, L, Merli, M, Passamonti, F, Onida, F, Morotti, A, Pavesi, F, Bregni, M, Broccoli, V, Baumann, M, Gambacorti-Passerini, C, Piazza, Rocco, Magistroni, Vera, Redaelli, Sara, Mauri, Mario, Massimino, Luca, Sessa, Alessandro, Peronaci, Marco, Lalowski, MacIej, Soliymani, Rabah, Mezzatesta, Caterina, Pirola, Alessandra, Banfi, Federica, Rubio, Alicia, Rea, Delphine, Stagno, Fabio, Usala, Emilio, Martino, Bruno, Campiotti, Leonardo, Merli, Michele, Passamonti, Francesco, Onida, Francesco, Morotti, Alessandro, Pavesi, Francesca, Bregni, Marco, Broccoli, Vania, Baumann, Marc, Gambacorti-Passerini, Carlo, Piazza, R, Magistroni, V, Redaelli, S, Mauri, M, Massimino, L, Sessa, A, Peronaci, M, Lalowski, M, Soliymani, R, Mezzatesta, C, Pirola, A, Banfi, F, Rubio, A, Rea, D, Stagno, F, Usala, E, Martino, B, Campiotti, L, Merli, M, Passamonti, F, Onida, F, Morotti, A, Pavesi, F, Bregni, M, Broccoli, V, Baumann, M, Gambacorti-Passerini, C, Piazza, Rocco, Magistroni, Vera, Redaelli, Sara, Mauri, Mario, Massimino, Luca, Sessa, Alessandro, Peronaci, Marco, Lalowski, MacIej, Soliymani, Rabah, Mezzatesta, Caterina, Pirola, Alessandra, Banfi, Federica, Rubio, Alicia, Rea, Delphine, Stagno, Fabio, Usala, Emilio, Martino, Bruno, Campiotti, Leonardo, Merli, Michele, Passamonti, Francesco, Onida, Francesco, Morotti, Alessandro, Pavesi, Francesca, Bregni, Marco, Broccoli, Vania, Baumann, Marc, and Gambacorti-Passerini, Carlo

Abstract

SETBP1 variants occur as somatic mutations in several hematological malignancies such as atypical chronic myeloid leukemia and as de novo germline mutations in the Schinzel-Giedion syndrome. Here we show that SETBP1 binds to gDNA in AT-rich promoter regions, causing activation of gene expression through recruitment of a HCF1/KMT2A/PHF8 epigenetic complex. Deletion of two AT-hooks abrogates the binding of SETBP1 to gDNA and impairs target gene upregulation. Genes controlled by SETBP1 such as MECOM are significantly upregulated in leukemias containing SETBP1 mutations. Gene ontology analysis of deregulated SETBP1 target genes indicates that they are also key controllers of visceral organ development and brain morphogenesis. In line with these findings, in utero brain electroporation of mutated SETBP1 causes impairment of mouse neurogenesis with a profound delay in neuronal migration. In summary, this work unveils a SETBP1 function that directly affects gene transcription and clarifies the mechanism operating in myeloid malignancies and in the Schinzel-Giedion syndrome caused by SETBP1 mutations.

Published
2018

9. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G, Breccia, M, Iurlo, A, Levato, L, Albano, F, Vigneri, Paolo, Abruzzese, E, Rossi, G, Rupoli, S, Cavazzini, F, Martino, B, Orlandi, E, Pregno, P, Annunziata, M, Usala, E, Tiribelli, M, Sica, S, Bonifacio, M, Fava, C, Gherlinzoni, F, Bocchia, M, Soverini, S, Bochicchio, Mt, Cavo, M, Giovanni, M, Saglio, G, Pane, F, Baccarani, M, Rosti, G, on behalf of the GIMEMA CML Working Party, Castagnetti, Fausto, Gugliotta, Gabriele, Breccia, Massimo, Iurlo, Alessandra, Levato, Luciano, Albano, Francesco, Vigneri, Paolo, Abruzzese, Elisabetta, Rossi, Giuseppe, Rupoli, Serena, Cavazzini, Francesco, Martino, Bruno, Orlandi, Ester, Pregno, Patrizia, Annunziata, Mario, Usala, Emilio, Tiribelli, Mario, Sica, Simona, Bonifacio, Massimiliano, Fava, Carmen, Gherlinzoni, Filippo, Bocchia, Monica, Soverini, Simona, Bochicchio, Maria Teresa, Cavo, Michele, Giovanni, Martinelli, Saglio, Giuseppe, Pane, Fabrizio, Baccarani, Michele, and Rosti, Gianantonio

Subjects
Oncology, Male, Transcription, Genetic, bcr-abl, Fusion Proteins, bcr-abl, BCR-ABL1, Chronic myeloid leukemia, Philadelphia chromosome, imatinib, prognosis, transcript type, cytogenetic response, 0302 clinical medicine, CHRONIC-PHASE, CYTOGENETIC RESPONSE, MOLECULAR-BIOLOGY, END-POINTS, 800 MG, RECOMMENDATIONS, SURVIVAL, CML, BREAKPOINT, E13A2, hemic and lymphatic diseases, 80 and over, Medicine, molecular biology, Chronic, Young adult, Prospective cohort study, Aged, 80 and over, breakpoint, Leukemia, Philadelphia Chromosome Positive, Myeloid leukemia, Hematology, Middle Aged, Prognosis, Treatment Outcome, 030220 oncology & carcinogenesis, Imatinib Mesylate, Female, Transcription, prognosi, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Socio-culturale, Antineoplastic Agents, Aged, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm Grading, Neoplasm Staging, Proportional Hazards Models, Protein Kinase Inhibitors, Young Adult, survival, 03 medical and health sciences, Genetic, Internal medicine, end points, chronic phase, cytogenetic response, molecular biology, end points, recommendations, survival, CML, breakpoint, chronic phase, business.industry, Proportional hazards model, Fusion Proteins, Imatinib, medicine.disease, Settore MED/15 - MALATTIE DEL SANGUE, Immunology, recommendations, BCR-ABL Positive, business, Myelogenous, 030215 immunology
Abstract

The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the prognostic significance of the BCR-ABL1 transcript type in early chronic phase CML have been published. Overall, these studies suggest that in e14a2 patients the response to imatinib is faster and deeper. To evaluate if the BCR-ABL1 transcript type (e13a2 compared to e14a2) affect the response to imatinib and the clinical outcome in newly diagnosed adult CML patients, 559 patients enrolled in 3 prospective studies (NCT00514488, NCT00510926, observational study CML/023) were analyzed. A qualitative PCR was performed at baseline: 52% patients had a e14a2 transcript, 37% a e13a2 transcript, 11% co-expressed both transcripts and 1% had other rare transcripts. The median follow-up was 76 months (95% of the patients had at least a 5-year observation). The complete cytogenetic response rates were comparable in e14a2 and e13a2 patients. The median time to MR(3.0) (6 and 12 months) and MR(4.0) (41 and 61 months) was significantly shorter for e14a2 patients compared to e13a2 patients, with a higher cumulative probability of MR(3.0) (88% and 83%, p

Published
2017

10. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

Author

Melillo, L., Tieghi, A., Candoni, A., Radaelli, F., Ciancia, R., Specchia, G., Martino, B., Scalzulli, P. R., Latagliata, R., Palmieri, F., Usala, E., Valente, D., Valvano, M. R., Cedrone, M., Comitini, G., Martinelli, V., Cascavilla, N., Gugliotta, L., Fanin, R., Iurlo, A., Zanella, A., Rotoli, B., Carluccio, P., Liso, V., Nobile, F., Santoro, C., Mazzucconi, M. G., Cantore, N., Angelucci, E., Annino, L., Cacciola, E., Cacciola, R., Giustolisi, R., Fanci, R., Bosi, A., Frungillo, N., Corradini, P., Patriarca, A., Dragani, A., De Muro, M., and Avvisati, G.

Subjects
Adult, Pediatrics, medicine.medical_specialty, Multivariate analysis, Adolescent, Alpha interferon, Abortion, Young Adult, Pregnancy, medicine, Humans, Registries, Retrospective Studies, Aspirin, Platelet Count, business.industry, Essential thrombocythemia, Obstetrics, Pregnancy Outcome, Retrospective cohort study, Hematology, Janus Kinase 2, Middle Aged, medicine.disease, Recombinant Proteins, Pregnancy Complications, Parity, Italy, Interferon Type I, Multivariate Analysis, Mutation, Gestation, Female, business, Live birth, Thrombocythemia, Essential
Abstract

Pregnancy is a high-risk event in women with essential thrombocythemia (ET). This observational study evaluated pregnancy outcome in ET patients focusing on the potential impact of aspirin (ASA) or interferon alpha (IFN) treatment during pregnancy. We retrospectively analyzed 122 pregnancies in 92 women consecutively observed in the last 10 years in 17 centers of the Italian thrombocythemia registry (RIT). The live birth rate was 75.4% (92/122 pregnancies). The risk of spontaneous abortion was 2.5-fold higher than in the control population (P < 0.01). ASA did not affect the live birth rate (71/93, 76.3% vs. 21/29, 72.4%, P = 0.67). However, IFN treatment during pregnancy was associated with a better outcome than was management without IFN (live births 19/20, 95% vs. 73/102, 71.6%, P = 0.025), and this finding was supported by multivariate analysis (OR: 0.10; 95% CI: 0.013-0.846, P = 0.034). The JAK2 V617F mutation was associated with a poorer outcome (fetal losses JAK2 V617F positive 9/25, 36% vs. wild type 2/24, 8.3%, P = 0.037), and this association was still significant after multivariate analysis (OR: 6.19; 95% CI: 1.17-32.61; P = 0.038). No outcome concordance between first and second pregnancies was found (P = 0.30). Maternal complications occurred in 8% of cases. In this retrospective study, in consecutively observed pregnant ET patients, IFN treatment was associated with a higher live birth rate, while ASA treatment was not. In addition, the JAK2 V617F mutation was confirmed to be an adverse prognostic factor.

Published
2009

11. LONG TERM OUTCOME OF INTERMITTENT IMATINIB TREATMENT POLICY FOR MANAGINGCHRONIC MYELOID LEUKEMIA IN THE ELDERLY

Author

Russo, Domenico, Malagola, Michele, Skert, C., Cancelli, V., Turri, D., Pregno, P., Pierri, I., Fogli, M., Testoni, N., De Vivo, A., Castagnetti, F., Pungolino, E., Stagno, F., Breccia, M., Martino, B., Intermesoli, T., Rege Cambrin, G., Nicolini, G., Abruzzese, E., Tiribelli, M., Bigazzi, C., Usala, E., Russo, S., Russo Rossi, A., Lunghi, M., Bocchia, M., D’Emilio, A., Santini, V., Girasoli, M., Di Lorenzo, R., Cesana, Bruno Mario, Soverini, S., Martinelli, G., Rosti, G., and Baccarani, M. .

Published
2015

12. LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY

Author

Gugliotta, G., Castagnetti, F., Breccia, M., Gozzini, A., Stagno, F., Rege Cambrin, G., Carella, A. M., Luciano, L., Abruzzese, E., Martino, B., Usala, E., Rossi, G., Bocchia, M., Cavazzini, Francesco, Tiribelli, M., Luatti, S., Venturi, C., Soverini, S., Cavo, M., Specchia, G., Alimena, G., Pane, F., Martinelli, G., Saglio, G., Rosti, G., and Baccarani, M.

Subjects
Socio-culturale
Published
2015

13. CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP

Author

Gugliotta, G, Castagnetti, F, Breccia, M, Stagno, F, Martino, B, Fava, Carmen, Luciano, L, Gozzini, A, Carella, Am, Abruzzese, E, Levato, L, Usala, E, Rossi, G, Bocchia, M, Tiribelli, M, Cavazzini, F, Salvucci, M, Cedrone, M, Trabacchi, E, Binotto, G, Venturi, C, Soverini, S, Cavo, M, Specchia, G, Alimena, G, Pane, F, Martinelli, G, Saglio, Giuseppe, Baccarani, M, and Rosti, G.

Subjects
Socio-culturale
Published
2015

14. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia

Author

Gambacorti-Passerini, C.B. Donadoni, C. Parmiani, A. Pirola, A. Redaelli, S. Signore, G. Piazza, V. Malcovati, L. Fontana, D. Spinelli, R. Magistroni, V. Gaipa, G. Peronaci, M. Morotti, A. Panuzzo, C. Saglio, G. Usala, E. Kim, D.-W. Rea, D. Zervakis, K. Viniou, N. Symeonidis, A. Becker, H. Boultwood, J. Campiotti, L. Carrabba, M. Elli, E. Bignell, G.R. Papaemmanuil, E. Campbell, P.J. Cazzola, M. Piazza, R.

Abstract

Despite the recent identification of recurrent SETBP1 mutations in atypical chronic myeloid leukemia (aCML), a complete description of the somatic lesions responsible for the onset of this disorder is still lacking. To find additional somatic abnormalities in aCML, we performed whole-exome sequencing on 15 aCML cases. In 2 cases (13.3%), we identified somatic missense mutations in the ETNK1 gene. Targeted resequencing on 515 hematological clonal disorders revealed the presence of ETNK1 variants in 6 (8.8%) of 68 aCML and 2 (2.6%) of 77 chronic myelomonocytic leukemia samples. These mutations clustered in a small region of the kinase domain, encoding for H243Y and N244S (1/8 H243Y; 7/8 N244S). They were all heterozygous and present in the dominant clone. The intracellular phosphoethanolamine/phosphocholine ratio was, on average, 5.2-fold lower in ETNK1-mutated samples ( P < .05). Similar results were obtained using myeloid TF1 cells transduced with ETNK1 wild type, ETNK1-N244S, and ETNK1-H243Y, where the intracellular phosphoethanolamine/phosphocholine ratio was significantly lower in ETNK1-N244S (0.76 ± 0.07) and ETNK1-H243Y (0.37 ± 0.02) than in ETNK1-WT (1.37 ± 0.32; P = .01 and P = .0008, respectively), suggesting that ETNK1 mutations may inhibit the catalytic activity of the enzyme. In summary, our study shows for the first time the evidence of recurrent somatic ETNK1 mutations in the context of myeloproliferative/myelodysplastic disorders. © 2015 by The American Society of Hematology.

Published
2015

15. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

16. HOW DIAGNOSTIC AND THERAPEUTIC APPROACHE CHANGED IN THE LAST DECADES IN THE PHILADELPHIA NEGATIVE MPN PATIENTS OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)

Author

Gugliotta, L., Iurio, A., Gugliotta, G., Alessia Tieghi, Candoni, A., Lunghi, M., Dragani, A., Antonioli, E., Scalzulli, P. R., Martinelli, V., Martino, B., Randi, M. L., Ricco, A., Appolloni, V., Maschio, N., Palmieri, R., Langella, M., Santoro, C., Rago, A., Ragionieri, R., Codeluppi, K., Cacciola, E., Cacciola, R., Mastrullo, L., Esposito, M. R., Caocci, G., Lanza, F., Rupoli, S., Pierri, I., Porretto, F., Melpignano, A., Crugnola, M., Di Ianni, M., Plebani, S., Molinari, E., Spinosa, G., Santoro, M., Villani, O., Ricciotti, M., Musolino, C., Usala, E., Falzetti, F., Biasi, E., Santoro, U., Federici, A., Vianelli, N., Mazzucconi, M. G., and Specchia, G.

Published
2015

17. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

Author

Gugliotta, L, Tieghi, A, Tortorella, G, Scalzulli, Pr, Ciancia, R, Lunghi, M, Cacciola, Emma, Cacciola, Rossella Rosaria, Candoni, A, Crugnola, M, Codeluppi, K, Usala, E, Specchia, G, Martinelli, V, Palmieri, F, Pierri, I, Liberati, M, Iurlo, A, Grossi, A, Vannucchi, Am, Vianelli, N, Mazzucconi, Mg, on behalf of the Registro Italiano Trombocitemai, Gugliotta, L, Tieghi, A, Tortorella, G, Scalzulli, Pr, Ciancia, R, Lunghi, M, Cacciola, E, Cacciola, R, Candoni, A, Crugnola, M, Codeluppi, K, Usala, E, Specchia, G, Martinelli, Vincenzo, Palmieri, F, Pierri, I, Liberati, Am, Iurlo, A, Grossi, A, Vannucchi, Am, Vianelli, N, and Mazzucconi, M. G.

Subjects
Male, Cancer Research, Adolescent, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Child, Cohort Studies, Drug-Related Side Effects and Adverse Reactions, Female, Follow-Up Studies, Humans, Middle Aged, Platelet Aggregation Inhibitors, Quinazolines, Retrospective Studies, Thrombocythemia, Essential, Withholding Treatment, Young Adult, Echocardiogram, Essential thrombocythemia, Essential, 80 and over, Palpitations, Medicine, Thrombocythemia, Hematology, Oncology, Anagrelide, Safety, Toxicity, Cardiovascular adverse events, Palpitation, Cohort, Cardiology, medicine.symptom, Cohort study, medicine.drug, medicine.medical_specialty, Internal medicine, Adverse effect, business.industry, Retrospective cohort study, medicine.disease, Discontinuation, business
Abstract

This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% for congestive heart failure, 1.8% for arrhythmia, 0.9% for AMI, 0.4% for pericardial effusion. CV-AEs led to treatment discontinuation in nine (3.9%) patients, while in the remaining cases they were managed by pharmacological intervention and/or patient life style improvement. CV-AEs had no relationship with patient characteristics (including older age). A significant relationship was found only with a higher anagrelide induction dose. In the absence of any agreed protocol, a cardiovascular instrumental evaluation (CV-IE) was performed in 102 (44%) patients before commencement of anagrelide (with higher rate after the anagrelide/Xagrid EMA approval of 2004), and in 84 (36%) patients during treatment. Patients with and without CV-IEs, who resulted completely balanced for all their characteristics, did not significantly differ in the occurrence of CV-AEs. In conclusion, this study on ET patients treated with anagrelide shows that CV-AEs, equally distributed in younger and older subjects, were mostly mild and easily manageable, allowing safe treatment continuation in the majority of cases. Moreover, routinely performing a CV-IE did not appear to anticipate the occurrence of CV-AEs.

Published
2011

18. Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph plus -CML

Author

Russo, D, Martinelli, G, Malagola, M, Cancelli, V, Skert, C, Soverini, S, Iacobucci, I, Turri, D, Mirto, S, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Fogli, M, Testoni, N, De Vivo, A, Castagnetti, F, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, A, Intermesoli, T, Saglio, G, Cambrin, Gr, Visani, G, Nicolini, G, de Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D'Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, Cesana, Bm, and Rosti, G

Published
2014

19. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Author

Breccia, M, Efficace, F, Sica, S, Abruzzese, E, Cedrone, M, Turri, D, Gobbi, M, Carella, A, Gozzini, A, Usala, E, Cavazzini, F, Danise, P, Tiribelli, M, Binotto, G, Pregno, P, Bocchia, M, Gaidano, G, Crugnola, M, Bonifacio, M, Avanzini, P, Celesti, F, Guella, A, Martino, B, Annunziata, M, Luciano, L, Stagno, F, Vallisa, D, Pungolino, E, Iurlo, A, Rambaldi, A, Nardiello, I, Orlandi, E, GAMBACORTI PASSERINI, C, Alimena, G, GAMBACORTI PASSERINI, CARLO, Alimena, G., Breccia, M, Efficace, F, Sica, S, Abruzzese, E, Cedrone, M, Turri, D, Gobbi, M, Carella, A, Gozzini, A, Usala, E, Cavazzini, F, Danise, P, Tiribelli, M, Binotto, G, Pregno, P, Bocchia, M, Gaidano, G, Crugnola, M, Bonifacio, M, Avanzini, P, Celesti, F, Guella, A, Martino, B, Annunziata, M, Luciano, L, Stagno, F, Vallisa, D, Pungolino, E, Iurlo, A, Rambaldi, A, Nardiello, I, Orlandi, E, GAMBACORTI PASSERINI, C, Alimena, G, GAMBACORTI PASSERINI, CARLO, and Alimena, G.

Abstract

Therapeutic approach for chronic myeloid leukemia (CML) patients has undergone a revolutionary change with the introduction of tyrosine kinase inhibitors, which improved overall survival and quality of life. Optimal therapy adherence has become of paramount importance to maximize the benefits in the long-term outcome. Several evidences have been reported that personal factors, such as social support, psychological and subjective perceptions about the drug used and the future, could influence adherence. We here report the results of a questionnaire specifically designed to evaluate factors influencing adherence and perceptions about the future, distributed to patients during regional Italian meetings. Overall, 1133 patients compiled the questionnaire: median age was 57 years. High rate of adherence was reported, but 42% of interviewed patients admitted that they had occasionally postponed a dose and 58% had discontinued therapy mainly for forgetfulness. The majority of patients discussed with personal physician about the importance of adherence and received sufficient information about illness and treatment, but would like to have discussed more about discomfort, anxiety and fear of the future. Summarizing personal drug compliance and estimating how many days a month, on average, the patients did not take the drug, the majority answered that it was less than 3 days (55%) and only a minority (4%) admitted that it was more than 7 days. Interviewed about discontinuation, 49% of patients answered that wouldn't interrupt because of fear of losing all the results achieved so far. This study suggests a higher level of satisfaction with more information received but the need of improving communication about possible future treatment free remission.

Published
2015

20. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, D'Emilio, A., Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, and D'Emilio, A.

Abstract

Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CMLWP over a 40-year period. Results: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). Conclusions: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.

Published
2015

21. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia

Author

GAMBACORTI PASSERINI, C, Donadoni, C, Parmiani, A, Pirola, A, Redaelli, S, Signore, G, Piazza, V, Malcovati, L, Fontana, D, Spinelli, R, Magistroni, V, Gaipa, G, Peronaci, M, Morotti, A, Panuzzo, C, Saglio, G, Usala, E, Kim, D, Rea, D, Zervakis, K, Viniou, N, Symeonidis, A, Becker, H, Boultwood, J, Campiotti, L, Carrabba, M, Elli, E, Bignell, G, Papaemmanuil, E, Campbell, P, Cazzola, M, Piazza, R, GAMBACORTI PASSERINI, CARLO, DONADONI, CARLA, PIROLA, ALESSANDRA, REDAELLI, SARA, FONTANA, DILETTA, SPINELLI, ROBERTA, MAGISTRONI, VERA, PERONACI, MARCO, PIAZZA, ROCCO GIOVANNI, GAMBACORTI PASSERINI, C, Donadoni, C, Parmiani, A, Pirola, A, Redaelli, S, Signore, G, Piazza, V, Malcovati, L, Fontana, D, Spinelli, R, Magistroni, V, Gaipa, G, Peronaci, M, Morotti, A, Panuzzo, C, Saglio, G, Usala, E, Kim, D, Rea, D, Zervakis, K, Viniou, N, Symeonidis, A, Becker, H, Boultwood, J, Campiotti, L, Carrabba, M, Elli, E, Bignell, G, Papaemmanuil, E, Campbell, P, Cazzola, M, Piazza, R, GAMBACORTI PASSERINI, CARLO, DONADONI, CARLA, PIROLA, ALESSANDRA, REDAELLI, SARA, FONTANA, DILETTA, SPINELLI, ROBERTA, MAGISTRONI, VERA, PERONACI, MARCO, and PIAZZA, ROCCO GIOVANNI

Abstract

Despite the recent identification of recurrent SETBP1 mutations in atypical chronic myeloid leukemia (aCML), a complete description of the somatic lesions responsible for the onset of this disorder is still lacking. To find additional somatic abnormalities in aCML, we performed whole-exome sequencing on 15 aCML cases. In 2 cases (13.3%), we identified somatic missense mutations in the ETNK1 gene. Targeted resequencing on 515 hematological clonal disorders revealed the presence of ETNK1 variants in 6 (8.8%) of 68 aCML and 2 (2.6%) of 77 chronic myelomonocytic leukemia samples. These mutations clustered in a small region of the kinase domain, encoding for H243Y and N244S (1/8 H243Y; 7/8 N244S). They were all heterozygous and present in the dominant clone. The intracellular phosphoethanolamine/phosphocholine ratio was, on average, 5.2-fold lower in ETNK1-mutated samples ( P < .05). Similar results were obtained using myeloid TF1 cells transduced with ETNK1 wild type, ETNK1-N244S, and ETNK1-H243Y, where the intracellular phosphoethanolamine/phosphocholine ratio was significantly lower in ETNK1-N244S (0.76 ± 0.07) and ETNK1-H243Y (0.37 ± 0.02) than in ETNK1-WT (1.37 ± 0.32; P = .01 and P = .0008, respectively), suggesting that ETNK1 mutations may inhibit the catalytic activity of the enzyme. In summary, our study shows for the first time the evidence of recurrent somatic ETNK1 mutations in the context of myeloproliferative/myelodysplastic disorders.

Published
2015

22. Cardiovascular events and intensity of treatment in polycythemia vera

Author

Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, De Stefano, V, Elli, E, Iurlo, A, Latagliata, R, Lunghi, F, Lunghi, M, Marfisi, Rm, Musto, P, Masciulli, A, Musolino, C, Cascavilla, N, Quarta, G, Randi, M. L., Rapezzi, D, Ruggeri, M, Rumi, E, Scortechini, Ar, Santini, S, Scarano, M, Siragusa, S, Spadea, A, Tieghi, A, Angelucci, E, Visani, G, Vannucchi, Am, Specchia G, Barbui T., D'Amico, A, Ferri, B, Guido, C, Marfisi, L, Pera, C, Polidoro, A, Sacco, M, Levantesi, G, Tognoni, G, Barosi, G, Carobbio, A, Leoni, P, Mulattieri, S, Tomassetti, S, Honorati, E, Ricco, A, Albano, F, Pastore, D, Carluccio, P, Mazzone, Am, Rossi, Ar, Finazzi, Mc, Delaini, F, Falanga, A, Rambaldi, A, Guaragna, G, Giannotta, A, Usala, E, Simula, Mp, Pilo, F, Cacciola, E, Pezzella, F, Seria, E, Di Francesco, E, Gallamini, A, Bertolotti, L, Antonioli, E, Guglielmelli, P, Pieri, L, Susini, Mc, Bartalucci, N, Bosi, A, D'Angelo, A, Centorrino, R, Gerace, D, Allegra, A, Cortelezzi, A, De Philippis, C, Ferretti, E, Ciceri, F, Claudiani, S, Malato, S, Trinca, S, Pogliani, Em, Belotti, A, Lanzi, E, Elli, Em, Gaidano, G, Deambrogi, C, Rossi, D, Saglio, G, Rotolo, A, Zanone, C, Bertozzi, I, Tezza, F, Aneloni, V, Quintini, G, Saccullo, G, Caracciolo, C, Cazzola, M, Casetti, I, Elena, C, Landini, B, Barulli, S, Guiducci, B, Lucesole, M, Malerba, L, Isidori, A, Grossi, A, De Stefanis, M, Biagioni, C, Merli, F, Imovilli, A, Codeluppi, K, Rubagotti, S, Romano, N, Bonini, A, Bellesia, E, Martorelli, Mc, Villani, O, Zifarone, E, Zonno, A, Santopietro, V, Za, T, Rossi, E, Ciminello, Am, Betti, S, Alimena, G, Tafuri, A, Breccia, M, Carmosino, I, Pisani, F, Romano, A, D'Andrea, M, Nobile, M, Mantuano, Fs, Rossi, G, Tricarico, M, Rodeghiero, F, Bedin, F, Lissandrini, L, Finotto, S., Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, De Stefano, V, Elli, E, Iurlo, A, Latagliata, R, Lunghi, F, Lunghi, M, Marfisi, RM, Musto, P, Masciulli, A, Musolino, C, Cascavilla, N, Quarta, G, Randi, ML, Rapezzi, D, Ruggeri, M, Rumi, E, Scortechini, AR, Santini, S, Scarano, M, Siragusa, S, Spadea, A, Tieghi, A, Angelucci, E, Visani, G, Vannucchi, AM, Barbui, T, and CYTO-PV Collaborative Group.

Subjects
Male, Hematocrit, RECURRENT THROMBOSIS, law.invention, Aged, Antineoplastic Agents, Cardiovascular Diseases, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Hydroxyurea, Janus Kinase 2, Middle Aged, Polycythemia Vera, Thrombosis, Phlebotomy, Medicine (all), LEUKOCYTOSIS, Polycythemia vera, Randomized controlled trial, law, hemic and lymphatic diseases, ESSENTIAL THROMBOCYTHEMIA, Clinical endpoint, Polycythemia Vera, Secondary Prophylaxis, ESSENTIAL THROMBOCYTHEMIA, RECURRENT THROMBOSIS, RISK-FACTOR, HEMATOCRIT, MANAGEMENT, LEUKOCYTOSIS, PREVENTION, DIAGNOSIS, EFFICACY, WARFARIN, medicine.diagnostic_test, Hazard ratio, General Medicine, medicine.medical_specialty, randomized trial, polycythemia vera, Cardiovascular event, DIAGNOSIS, WARFARIN, RISK-FACTOR, Internal medicine, MANAGEMENT, medicine, Myelofibrosis, Adverse effect, business.industry, EFFICACY, medicine.disease, PREVENTION, Surgery, Polycythemia Vera, Cardiovascular event, hematocrit, Settore MED/15 - MALATTIE DEL SANGUE, business
Abstract

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit

Published
2013

23. EARLY PREDICTORS OF PROGRESSION TO ACCELERATED-BLASTIC PHASE IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS

Author

Gugliotta, G., Castagnetti, F., FRANCESCA PALANDRI, Breccia, M., Levato, L., Stagno, F., Cambrin, G. Rege, Zaccaria, A., Specchia, G., Usala, E., Gozzini, A., Martino, B., Capucci, A., Pierri, I., Tiribelli, M., Bocchia, M., Abruzzese, E., Soverini, S., Testoni, N., Saglio, G., Martinelli, G., Pane, F., Alimena, G., Rosti, G., Baccarani, M., G Gugliotta, F Castagnetti, F Palandri, M Breccia, L Levato, F Stagno, G Rege Cambrin, A Zaccaria, G Specchia, E Usala, A Gozzini, B Martino, A Capucci, I Pierri, M Tiribelli, M Bocchia, E Abruzzese, S Soverini, N Testoni, G Saglio, G Martinelli, F Pane, G Alimena, G Rosti, and M Baccarani

Subjects
CHRONIC MYELOID LEUKEMIA (CML)
Published
2012

24. EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS

Author

Castagnetti, F., Gugliotta, G., FRANCESCA PALANDRI, Breccia, M., Levato, L., Stagno, F., Specchia, G., Cambrin, G. Rege, Luciano, L., Gozzini, A., Martino, B., Capucci, A., Intermesoli, T., Tiribelli, M., Cedrone, M., Cavazzini, F., Usala, E., Soverini, S., Testoni, N., Pane, F., Saglio, G., Alimena, G., Martinelli, G., Rosti, G., Baccarani, M., F Castagnetti, G Gugliotta, F Palandri, M Breccia, L Levato, F Stagno, G Specchia, G Rege Cambrin, L Luciano, A Gozzini, B Martino, A Capucci, T Intermesoli, M Tiribelli, M Cedrone, F Cavazzini, E Usala, S Soverini, N Testoni, F Pane, G Saglio, G Alimena, G Martinelli, G Rosti, and M Baccarani.

Subjects
NILOTINIB, CHRONIC MYELOID LEUKEMIA (CML)
Published
2012

25. BCR-ABL FUSION TRANSCRIPT AND OUTCOME OF CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY CHRONIC PHASE TREATED WITH IMATINIB: A GIMEMA CML WP ANALYSIS

Author

Castagnetti, F., Gugliotta, G., Palandri, F., Breccia, M., Specchia, G., Abruzzese, E., Levato, L., Cavazzini, Francesco, Orlandi, E., Stagno, F., Di Lorenzo, R., Annunziata, M., Usala, E., Sica, S., Galieni, P., Rege Cambrin, G., Amabile, M., Soverini, S., Testoni, N., Alimena, G., Martinelli, G., Pane, F., Saglio, G., Baccarani, M., and Rosti, G.

Published
2011

26. THE BCR-ABL FUSION TRANSCRIPT HAS A PROGNOSTIC IMPACT IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A GIMEMA CML WP ANALYSIS

Author

Castagnetti, F, Gugliotta, G, Palandri, F, Breccia, M, Specchia, G, Abruzzese, E, Levato, L, Cavazzini, F, Orlandi, E, Stagno, F, Di Lorenzo, R, Annunziata, M, Usala, E, Sica, S, Galieni, P, Rege-Cambrin, G, Amabile, M, Soverini, S, Testoni, N, Alimena, G, Martinelli, G, Pane, F, Saglio, G, Baccarani, M, and Rosti, G for the GIMEMA CML Working Party

Published
2011

27. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

Author

Russo, D, primary, Malagola, M, additional, Skert, C, additional, Cancelli, V, additional, Turri, D, additional, Pregno, P, additional, Bergamaschi, M, additional, Fogli, M, additional, Testoni, N, additional, De Vivo, A, additional, Castagnetti, F, additional, Pungolino, E, additional, Stagno, F, additional, Breccia, M, additional, Martino, B, additional, Intermesoli, T, additional, Cambrin, G R, additional, Nicolini, G, additional, Abruzzese, E, additional, Tiribelli, M, additional, Bigazzi, C, additional, Usala, E, additional, Russo, S, additional, Russo-Rossi, A, additional, Lunghi, M, additional, Bocchia, M, additional, D'Emilio, A, additional, Santini, V, additional, Girasoli, M, additional, Lorenzo, R Di, additional, Bernardi, S, additional, Palma, A Di, additional, Cesana, B M, additional, Soverini, S, additional, Martinelli, G, additional, Rosti, G, additional, and Baccarani, M, additional

Published
2015
Full Text
View/download PDF

28. LOW DOSE CONTINUOUS THERAPY WITH DASATINIB SIGNIFICANTLY IMPACT ON SURVIVAL OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) RESISTANT OR INTOLERANT TO IMATINIB. RESULTS FROM A REAL LIFE-BASED ITALIAN MULTICENTER RETROSPECTIVE STUDY ON 114 UNSELECTED PATIENTS

Author

Visani, G, Breccia, M, Gozzini, A, Specchia, G, Montefusco, E, Morra, E, Annunziata, M, Luciano, L, Camera, A, Cavazzini, F, Stagno, F, Di Raimondo, F, Pregno, P, Santini, V, Piccaluga, P, Pacilli, M, Pungolino, E, Usala, E, Angelucci, E, Cuneo, A, Ferrara, F, Crugnola, M, Binotto, G, Maino, E, Latagliata, R, Nicolini, R, Barulli, S, Loscocco, F, Alimena, G, and Isidori, A

Published
2010

29. LOW DOSE CONTINUOUS THERAPY WITH DASATINIB SIGNIFICANTLY IMPACT ON SURVIVAL OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) RESISTANT OR INTOLERANT TO IMATINIB. RESULTS FROM A REAL LIFE-BASED ITALIAN MULTICENTER RETROSPECTIVE STUDY ON 114 UNSELECTED PATIENTS

Author

Visani, G., Breccia, M., Gozzini, A., Specchia, G., Montefusco, E., Morra, E., Annunziata, M., Luciano, L., Camera, A., Cavazzini, Francesco, Stagno, F., Di Raimondo, F., Pregno, P., Santini, V., Piccaluga, P., Pacilli, M., Pungolino, E., Angelucci, E. Usala E., Cuneo, Antonio, Ferrara, F., Crugnola, M., Binotto, G., Maino, E., Latagliata, R., Nicolini, G., Barulli, S., Loscocco, F., Alimena, G., and Isidori, A.

Published
2010

30. MONITORING OF COMPLETE CYTOGENETIC RESPONSE (CCGR) BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (I-FISH) ON PERIPHERAL BLOOD IN ELDERLY PH+ CML PATIENTS WITH STABLE CCGR TREATED WITH INTERMITTENT IMATINIB (IM)EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806

Author

Russo, Domenico, Malagola, Michele, Testoni, N, Martinelli, G, Colombi, C, Skert, C, Rosti, G, Amabile, M, Fogli, M, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, R, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D’Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, De Vivo, A, Soverini, S, Iacobucci, I, and Baccarani, M.

Published
2010

31. PRE-FINAL ANALYSIS OF THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PH+ CML PATIENTS WITH STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) – EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806

Author

Russo, Domenico, Martinelli, G, Malagola, Michele, Colombi, C, Rosti, G, Amabile, M, Fogli, M, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, R, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D’Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, and Di Lorenzo, R.

Published
2010

32. One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly ( 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806

Author

Russo, D, Martinelli, G, Malagola, M, Colombi, C, Rosti, G, Amabile, M, Fogli, M, Turri, D, Mirto, S, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, A, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, de Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Specchia, G, Liso, V, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D'Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, Testoni, N, De Vivo, A, Soverini, S, Iacobucci, I, and Baccarani, M

Published
2010

33. PRE-FINAL ANALYSIS OF THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PH+ CML PATIENTS WITH STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) – EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806

Author

Russo, D, Martinelli, G, Malagola, M, Colombi, C, Rosti, G, Amabile, M, Fogli, M, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Morra, E, Pungolino, E, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Nobile, F, Martino, B, Rambaldi, R, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Rodeghiero, F, D’Emilio, A, Bosi, A, Santini, V, Quarta, G, Girasoli, M, Fioritoni, G, Di Lorenzo, R, Testoni, N, De Vivo, A, Soverini, S, Iacobucci, I, and Baccarani, M

Published
2010

34. UPDATE OF CYTOGENETIC AND MOLECULAR RESPONSE IN 88 ELDERLY PH+ CHRONIC MYELOID LEUKEMIA PATIENTS ENROLLED IN THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM)

Author

Russo, Domenico, Rosti, G., Martinelli, G., Malagola, Michele, Mirto, S., Turri, D., Gobbi, M., Pierri, I., Vitolo, U., Pregno, P., Morra, E., Pungolino, E., Di Raimondo, F., Stagno, F., Foà, R., Alimena, G., Breccia, M., Nobile, F., Martino, B., Rambaldi, A., Intermesoli, T., Saglio, G., Rege Cambrin, G., Visani, G., Nicolini, G., De Fabritiis, P., Abruzzese, E., Fanin, R., Tiribelli, M., Galieni, P., Bigazzi, C., Liso, V., Specchia, G., Angelucci, E., Usala, E., Musolino, C., Russo, S., Gaidano, G., Lunghi, M., Lauria, F., Bocchia, M., D’Emilio, A., Bosi, A., Sanitini, V., Quarta, G., Girasoli, M., Fioritoni, G., Di Lorenzo, R., Colombi, C., Fogli, M., Amabile, 2 M., Testoni, N., De Vivo, A., and Baccarani, M.

Published
2010

35. Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia

Author

Donadoni, C, Piazza, R, Fontana, D, Parmiani, A, Pirola, A, Redaelli, S, Signore, G, Piazza, V, Malcovati, L, Spinelli, R, Magistroni, V, Gaipa, G, Peronaci, M, Morotti, A, Panuzzo, C, Saglio, G, Elli, E, Usala, E, Kim, D, Rea, D, Zervakis, K, Viniou, N, Symeonidis, A, Becker, H, Boultwood, J, Campiotti, L, Carrabba, M, Bignell, G, Papaemmanuil, E, Campbell, P, Cazzola, M, GAMBACORTI PASSERINI, C, DONADONI, CARLA, PIAZZA, ROCCO GIOVANNI, FONTANA, DILETTA, PIROLA, ALESSANDRA, REDAELLI, SARA, SPINELLI, ROBERTA, MAGISTRONI, VERA, GAIPA, GIUSEPPE, PERONACI, MARCO, ELLI, ELENA MARIA, GAMBACORTI PASSERINI, CARLO, Donadoni, C, Piazza, R, Fontana, D, Parmiani, A, Pirola, A, Redaelli, S, Signore, G, Piazza, V, Malcovati, L, Spinelli, R, Magistroni, V, Gaipa, G, Peronaci, M, Morotti, A, Panuzzo, C, Saglio, G, Elli, E, Usala, E, Kim, D, Rea, D, Zervakis, K, Viniou, N, Symeonidis, A, Becker, H, Boultwood, J, Campiotti, L, Carrabba, M, Bignell, G, Papaemmanuil, E, Campbell, P, Cazzola, M, GAMBACORTI PASSERINI, C, DONADONI, CARLA, PIAZZA, ROCCO GIOVANNI, FONTANA, DILETTA, PIROLA, ALESSANDRA, REDAELLI, SARA, SPINELLI, ROBERTA, MAGISTRONI, VERA, GAIPA, GIUSEPPE, PERONACI, MARCO, ELLI, ELENA MARIA, and GAMBACORTI PASSERINI, CARLO

Published
2014

37. PHASE II MULTICENTRIC EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA (CML) WHO ACHIEVED A STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) WITH STANDARD IM THERAPY

Author

Russo, D., Rosti, G., Martinelli, G., Malagola, M., Mirto, S., Turri, D., Gobbi, M, Pierri, I., Vitolo, U., Pregno, P., Di Raimondo, F., Stagno, F., Foà, R., Alimena, G., Breccia, M, Rambaldi, R., Intermesoli, T, Saglio, G., Rege Cambrin, G., Visani, G., Nicolini, G., De Fabritiis, P., Abruzzese, E., Nobile, F., Martino, B., Fanin, R., Tiribelli, M., Galieni, P., Bigazzi, C., Liso, V., Specchia, G., Angelucci, E., Usala, E., Musolino, C., Russo, S., Gaidano, G. ., Lunghi, M., Lauria, F., Bocchia, M., Quarta, G., Girasoli, M., Bosi, A., Santini, V., Fioritoni, G., Di Lorenzo, R., Colombi, C., Fogli, M., Amabile, M., and De Vivo, A. Baccarani M.

Published
2009

38. Phase II multicentric explorative study of Intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with standard IM therapy

Author

Russo, Domenico, Rosti, G, Martinelli, G, Malagola, Michele, Mirto, S, Turri, D, Gobbi, M, Pierri, I, Vitolo, U, Pregno, P, Di Raimondo, F, Stagno, F, Foà, R, Alimena, G, Breccia, M, Rambaldi, A, Intermesoli, T, Saglio, G, Rege Cambrin, G, Visani, G, Nicolini, G, De Fabritiis, P, Abruzzese, E, Nobile, F, Martino, B, Fanin, R, Tiribelli, M, Galieni, P, Bigazzi, C, Liso, V, Specchia, G, Angelucci, E, Usala, E, Musolino, C, Russo, S, Gaidano, G, Lunghi, M, Lauria, F, Bocchia, M, Quarta, G, Girasoli, M, Bosi, A, Santini, V, Fioritoni, G, Di Lorenzo, R, Colombi, C, Fogli, M, Amabile, M, De Vivo, A, and B. a. c. c. a. r. a. n. i. M.

Published
2009

45. Anagrelide treatment and cardiovascular evaluation in 130 patients with essential thrombocythemia (ET): Preliminary report of the Registro Italiano Trombocitemia (RIT)

Author

Gugliotta, L., Tieghi, A., Bulgarelli, S., Tortorella, C., Ciancia, R., Scalzulli, Pr, Cacciola, E., Cacciola, R., Rossi, D., Usala, E., Crugnola, M., Candoni, A., Giordano M, Andriani A., Santoro, Cristina, Vimercati, R., Liberati, M., Sciorio A., Specchia G., Martinelli, V., Gaidano, G., and Mazzucconi, Maria Gabriella

Published
2005

46. Anagrelide treatment and cardiovascular evaluation in 130 patients with assential trombo-cythemia (ET): preliminary report of the Registro Italiano Trombocitemia (RIT)

Author

Luigi, Gugliotta, Tieghi, A., Bulgarelli, S., Tortorella, G., Ciancia, R., Scalzulli, P. R., Cacciola, E, Cacciola, Rossella Rosaria, Rossi, D., Usala, E., Prugnola, M., Candoni, A., Giordano, M., Andrani, A., Santoro, C., Vimercati, R., Liberati, M., Sciorio, A., Specchia, G., MARTI NELLI, V., Gaidano, G., and Nazzucconi, M. G.

Published
2005

49. Anagrelide Treatment and Cardiovascular Evaluation in 130 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia (RIT).

Author

Gugliotta, Luigi, primary, Tieghi, A., primary, Bulgarelli, S., primary, Tortorella, G., primary, Ciancia, R., primary, Scalzulli, P. R., primary, Cacciola, E., primary, Cacciola, R., primary, Rossi, D., primary, Usala, E., primary, Crugnola, M., primary, Candoni, A., primary, Giordano, M., primary, Andriani, A., primary, Santoro, C., primary, Vimercati, R., primary, Liberati, M., primary, Sciorio, A., primary, Specchia, G., primary, Martinelli, V., primary, Gaidano, G., primary, and Mazzucconi, M. G., primary

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results